CA3064975A1 - Nouveaux inhibiteurs de map4k1 - Google Patents

Nouveaux inhibiteurs de map4k1 Download PDF

Info

Publication number
CA3064975A1
CA3064975A1 CA3064975A CA3064975A CA3064975A1 CA 3064975 A1 CA3064975 A1 CA 3064975A1 CA 3064975 A CA3064975 A CA 3064975A CA 3064975 A CA3064975 A CA 3064975A CA 3064975 A1 CA3064975 A1 CA 3064975A1
Authority
CA
Canada
Prior art keywords
phenyl
oxy
trifluoromethyl
oxazin
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3064975A
Other languages
English (en)
Inventor
Vinod Patel
Venkateshwar Reddy
Laxmikant Atmaram Gharat
Sachin Sundarial CHAUDHARI
Sanjib Das
Ranganadh Velgaleti
Daisy Manish Shah
Malini Bajpai
Original Assignee
Ichnos Sciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichnos Sciences SA filed Critical Ichnos Sciences SA
Publication of CA3064975A1 publication Critical patent/CA3064975A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne de nouveaux inhibiteurs de MAP4K1 (HPK1) utiles pour le traitement de maladies ou de troubles caractérisés par un dérèglement des voies de transduction de signal associées à l'activation MAPK, y compris des maladies hyperprolifératives, des maladies du dysfonctionnement du système immunitaire, des troubles inflammatoires, des maladies neurologiques et des maladies cardiovasculaires. L'invention concerne en outre des compositions pharmaceutiques comprenant lesdits inhibiteurs et des méthodes de traitement desdites maladies et troubles. Les inhibiteurs de l'invention sont représentés par la formule (I), dans laquelle les définitions pour A, D, E, F, R5, R6, R7, Z, le cycle Q, n, x et y sont tels que définis dans la description.
CA3064975A 2017-05-26 2018-05-28 Nouveaux inhibiteurs de map4k1 Abandoned CA3064975A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762511455P 2017-05-26 2017-05-26
US62/511,455 2017-05-26
US201762544531P 2017-08-11 2017-08-11
US62/544,531 2017-08-11
PCT/EP2018/063957 WO2018215668A1 (fr) 2017-05-26 2018-05-28 Nouveaux inhibiteurs de map4k1

Publications (1)

Publication Number Publication Date
CA3064975A1 true CA3064975A1 (fr) 2018-11-29

Family

ID=62492619

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3064975A Abandoned CA3064975A1 (fr) 2017-05-26 2018-05-28 Nouveaux inhibiteurs de map4k1

Country Status (10)

Country Link
EP (1) EP3630778A1 (fr)
JP (1) JP2021506735A (fr)
KR (1) KR20200011965A (fr)
CN (1) CN112601752A (fr)
AU (1) AU2018272986A1 (fr)
CA (1) CA3064975A1 (fr)
EA (1) EA201992584A1 (fr)
IL (1) IL270844A (fr)
MX (1) MX2019013922A (fr)
WO (1) WO2018215668A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
WO2020092528A1 (fr) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1
US20220047603A1 (en) 2018-12-11 2022-02-17 Bayer Aktiengesellschaft Substituted pyrrolopyridine-derivatives
CA3129772A1 (fr) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Inhibiteurs bicycliques de hpk1
US12492194B2 (en) 2019-03-26 2025-12-09 Janssen Pharmaceutica Nv HPK1 inhibitors
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
US12612424B2 (en) 2019-07-04 2026-04-28 Regor Pharmaceuticals, Inc. HPK1 inhibitors and uses thereof
CN114144410A (zh) * 2019-07-19 2022-03-04 阿纳格纳斯生物技术股份有限公司 多芳基脲衍生物及其在治疗肌肉疾病中的用途
EP4103540B1 (fr) * 2020-02-13 2023-11-01 BASF Agro B.V. Procédé pour la préparation de 1-[4-nitro-2-(trifluorométhyl)phényl]-alkanones
PH12022553024A1 (en) 2020-05-08 2024-05-20 Halia Therapeutics Inc Inhibitors of nek7 kinase
WO2021249913A1 (fr) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft Dérivés de 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azétidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate et des composés apparentés servant d'inhibiteurs de map4k1 (hpk1) pour le traitement du cancer
AU2021307560A1 (en) 2020-07-15 2023-02-23 Chiesi Farmaceutici S.P.A. Pyrido oxazine amino derivatives as ALK5 inhibitors
CN112225748B (zh) * 2020-10-20 2021-11-30 四川大学华西医院 一种具有flt3激酶抑制活性的小分子化合物及其应用
CN114539065B (zh) * 2020-11-25 2023-07-25 帕潘纳(北京)科技有限公司 制备4-硝基-2-三氟甲基苯乙酮的方法
EP4267584A1 (fr) 2020-12-23 2023-11-01 Chiesi Farmaceutici S.p.A. Dérivés de pyrido-oxazine utilisés comme inhibiteurs d'alk5
EP4029501A1 (fr) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combinaison de dérivés polyaromatiques de l'urée et d'inhibiteur glucocorticoïde ou hdac pour le traitement de maladies ou d'affections associées aux cellules musculaires et/ou aux cellules satellites
US20240174683A1 (en) 2021-02-05 2024-05-30 Bayer Aktiengesellschaft Map4k1 inhibitors
KR20230175222A (ko) 2021-04-05 2023-12-29 할리아 테라퓨틱스, 인코포레이티드 Nek7 억제제
WO2022226182A1 (fr) 2021-04-22 2022-10-27 Halia Therapeutics, Inc. Inhibiteurs de nek7
CN113603635B (zh) * 2021-10-08 2021-12-24 湖南速博生物技术有限公司 一种芳香族二元羧酸酯水解脱羧的方法
CN116410203B (zh) * 2021-12-29 2024-06-25 四川大学 具有trk及其耐药突变抑制活性的化合物及其应用
CN114751874B (zh) * 2022-05-30 2025-01-24 江南大学 作为TRPV4-KCa2.3促耦联剂的1-苄基-4-乙基哌嗪衍生物及其应用
EP4289427A1 (fr) * 2022-06-10 2023-12-13 Anagenesis Biotechnologies Dihydro[1,8]naphthyridin-7-one et pyrido[3,2-b][1,4]oxazin-3-one pour une utilisation dans le traitement du cancer, et des métastases en particulier.
WO2024059200A1 (fr) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Inhibiteurs de nek7
CN117049938B (zh) * 2023-06-20 2024-06-14 山东轩德医药科技有限公司 一种6-溴-2,3-二氟甲苯的制备方法
CN116969831B (zh) * 2023-08-01 2025-09-23 菏泽皓元医药科技有限公司 一种莫奈太尔的中间体及其制备方法
CN121574078A (zh) * 2026-01-20 2026-02-27 天津楷特药业有限公司 一种3-(二氟甲磺酰基)苯甲酸类化合物的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415987B1 (fr) * 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Composes heteroaromatiques azotes pour le traitement des maladies de cancer
MX2012001419A (es) * 2009-08-06 2012-03-16 Merck Patent Gmbh Compuestos biciclicos novedosos de urea.
AU2012294917A1 (en) * 2011-08-10 2014-03-20 Merck Patent Gmbh Pyrido-pyrimidine derivatives
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives

Also Published As

Publication number Publication date
JP2021506735A (ja) 2021-02-22
CN112601752A (zh) 2021-04-02
EA201992584A1 (ru) 2020-06-18
KR20200011965A (ko) 2020-02-04
AU2018272986A1 (en) 2019-12-12
IL270844A (en) 2020-01-30
MX2019013922A (es) 2020-08-17
WO2018215668A1 (fr) 2018-11-29
EP3630778A1 (fr) 2020-04-08

Similar Documents

Publication Publication Date Title
WO2018215668A1 (fr) Nouveaux inhibiteurs de map4k1
US12344595B2 (en) 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors
US11952380B2 (en) Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
US10358446B2 (en) Bruton's tyrosine kinase inhibitors
CA3204823A1 (fr) Inhibiteurs de prmts
US20240208909A1 (en) Substituted quinoline derivatives having sos1 inhibition activities and uses thereof
CN104903321B (zh) 作为激酶抑制剂的经取代三环苯并咪唑
TW202144345A (zh) Ｋｒａｓ突變蛋白抑制劑
CN116514846A (zh) 杂环类衍生物、其制备方法及其医药上的用途
EP2828259B1 (fr) Composés de pyridopyrimidine substituée et leur utilisation comme inhibiteurs de flt3
AU2016226340B2 (en) Bicyclic ketone sulfonamide compounds
US10336755B2 (en) Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases
CA2932008A1 (fr) Derives benzimidazoles tricycliques condenses comme modulateurs de l'activite du tnf
US10266491B2 (en) Carbazole derivatives
KR20250121029A (ko) 두드러기 치료를 위한 야생형 c-kit 키나제 억제제로서의 n-페닐-피라졸로[1,5-a]피리딘-3-카르복사미드 유도체
JP2018009024A (ja) カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
WO2012000632A1 (fr) Pyrazoloquinoléines
JP7826325B2 (ja) Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための７－アザインドール化合物
US20130245002A1 (en) Triazolopyridine Compounds
CN121985945A (zh) 作为c-KIT激酶抑制剂的药物化合物和组合物
KR20190067788A (ko) Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물
EP4617273A1 (fr) Inhibiteur de parp1 tricyclique fusionné, son procédé de préparation et son utilisation
CA3074059A1 (fr) Derives de 2-azabicyclo[3.1.1]heptane et de 2-azabicyclo[3.2.1]octane substitues en tant qu'antagonistes du recepteur de l'orexine
WO2022170164A1 (fr) Sulfonamides ayant des activités d'inhibition de l'egfr et leur utilisation
CN121487934A (zh) 能够用于治疗smarca4缺失型癌症的作为smarca2抑制剂的1.6-萘啶化合物

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20221129